"VARSITY: Entyvio Beats Humira in Ulcerative Colitis" - Joan-Marie Stiglich
According to researchers at the Icahn School of Medicine at Mount Sinai, clinical and endoscopic outcomes of Entyvio treatment were superior to those of Humira in moderately to severely active ulcerative colitis at one year. Bruce Sands, MD, chief of the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and co-author of the study said, “We all know that biologic therapy is a very important part of the management of patients with ulcerative colitis, but unfortunately there has been a paucity of direct comparative clinical data to inform the choice of biologic options. VARSITY is the first head-to-head trial comparing two biologic therapies for ulcerative colitis.” He added, “In terms of safety and tolerability, I would say that both drugs behaved in a very safe way according to what we already know about their excellent safety profiles.”
— Bruce Sands, MD, Professor, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai, Chief, Division of Gastroenterology, Mount Sinai Health System
